Jeremy Barton, M.D. is Chief Medical Advisor at Acrivon Therapeutics, Inc. Jeremy has over 29 years of experience in all phases of oncology drug development in the pharmaceutical industry in Switzerland, UK and currently in the US. Most recent industry responsibilities have included Chief Medical Officer roles at Biogen Idec, eFFECTOR Therapeutics and Mirati Therapeutics. He was also head of early Oncology Development at Pfizer for 5 years overseeing the transition of all Oncology compounds from research through IND to proof-of-concept studies.
After obtaining a Master’s degree in Physiology from Oxford University and his M.D. degree at University College Hospital Medical School in London, he trained in Internal Medicine and Clinical Oncology in the United Kingdom and practiced for 11 years in the National Health Service. Jeremy is Board Certified in Internal Medicine and Clinical Oncology, a Member of the Royal College of Physicians, a Fellow of the Royal College of Radiologists (Clinical Oncology) and a Member of Faculty of Pharmaceutical Medicine.